A randomized placebo-controlled trial of vortioxetine for obsessive-compulsive disorder
Phase 2
- Conditions
- Health Condition 1: F42- Obsessive-compulsive disorder
- Registration Number
- CTRI/2023/12/060748
- Lead Sponsor
- Indican Council of Medical Research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
i. Patients diagnosed with OCD as per ICD 11 by a psychiatrist
ii. OCD rated as moderate to severe (YBOCS score 16+)
iii. Patients who are drug naïve or have not taken any SRIs for the last 7 days at least.
Exclusion Criteria
i. Patients with psychotic symptoms
ii. Patients with co-morbid major psychiatric illness
iii. Patients with comorbid substance use disorder in dependence pattern except tobacco
and caffeine.
iv. Pregnant and lactating mothers.
v. Patients with co-morbid medical or neurological illness
vi. Patients with history of adverse drug reaction to Vortioxetine in the past
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method